In fact, 3 patients with CANDLE on baricitinib treatment developed hepatic steatosis, which manifested as a moderate decrease in their BMIs from baseline, pointing to a role of proteasome dysfunction in the development of hepatic steatosis that is independent of IFN-mediated inflammation (22). Here, IFNA1 is linked to fatty liver disease.